Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)

Dominique Salmon-Ceron, Julien Cohen, Maria Winnock, Perrine Roux, Firouze Bani Sadr, Eric Rosenthal, Isabelle Poizot Martin, Marc-Arthur Loko, Marion Mora, Philippe Sogni, Bruno Spire, François Dabis, Maria Patrizia Carrieri, HEPAVIH group, D Salmon, F Dabis, M Winnock, M A Loko, P Sogni, Y Benhamou, P Trimoulet, J Izopet, V Paradis, B Spire, P Carrieri, C Katlama, G Pialoux, I Poizot-Martin, B Marchou, E Rosenthal, A Bicart See, M Bentata, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Vittecoq, D Neau, P Morlat, F BaniSadr, L Meyer, F Boufassa, S Dominguez, B Autran, A M Roque, C Solas, H Fontaine, G Chêne, D Costagliola, L Allain, D Salmon, F Dabis, M Winnock, Y Benhamou, P Sogni, J Izopet, P Trimoulet, B Spire, M P Carrieri, M Mora, J Cohen, P Roux, M Winnock, M A Loko, D Salmon, G Spiridon, F Almasi, O Eldbouni, P Sogni, C Katlama, M A Valantin, S Dominguez, Y Benhamou, A Gastaut, I Poizot-Martin, O Zaegel, G Pialoux, P Bonnard, F Bani-sadr, B Marchou, K Barange, S Metivier, E Rosenthal, C Pradier, A Krivitzky, M Bentata, M Uzan, A Bicart-See, D Garipuy, P Yéni, A Gervais, D Séréni, P M Girard, K Lacombe, J F Delfraissy, C Goujard, D Vittecoq, O Lortholary, C Duvivier, S Boucly, D Neau, P Morlat, I Raymond, I Louis, D Beniken, A Ivanova, A Fooladi, M Azar, P Honoré, S Breau, L Serini, M Mole, M Malet, C Bolliot, J Delaune, A Maignan, S Gillet, L Dequae Merchadou, E Pambrun, A Frosch, J Cohen, V Villes, P Kurkdji, M A Loko, M Winnock, Dominique Salmon-Ceron, Julien Cohen, Maria Winnock, Perrine Roux, Firouze Bani Sadr, Eric Rosenthal, Isabelle Poizot Martin, Marc-Arthur Loko, Marion Mora, Philippe Sogni, Bruno Spire, François Dabis, Maria Patrizia Carrieri, HEPAVIH group, D Salmon, F Dabis, M Winnock, M A Loko, P Sogni, Y Benhamou, P Trimoulet, J Izopet, V Paradis, B Spire, P Carrieri, C Katlama, G Pialoux, I Poizot-Martin, B Marchou, E Rosenthal, A Bicart See, M Bentata, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Vittecoq, D Neau, P Morlat, F BaniSadr, L Meyer, F Boufassa, S Dominguez, B Autran, A M Roque, C Solas, H Fontaine, G Chêne, D Costagliola, L Allain, D Salmon, F Dabis, M Winnock, Y Benhamou, P Sogni, J Izopet, P Trimoulet, B Spire, M P Carrieri, M Mora, J Cohen, P Roux, M Winnock, M A Loko, D Salmon, G Spiridon, F Almasi, O Eldbouni, P Sogni, C Katlama, M A Valantin, S Dominguez, Y Benhamou, A Gastaut, I Poizot-Martin, O Zaegel, G Pialoux, P Bonnard, F Bani-sadr, B Marchou, K Barange, S Metivier, E Rosenthal, C Pradier, A Krivitzky, M Bentata, M Uzan, A Bicart-See, D Garipuy, P Yéni, A Gervais, D Séréni, P M Girard, K Lacombe, J F Delfraissy, C Goujard, D Vittecoq, O Lortholary, C Duvivier, S Boucly, D Neau, P Morlat, I Raymond, I Louis, D Beniken, A Ivanova, A Fooladi, M Azar, P Honoré, S Breau, L Serini, M Mole, M Malet, C Bolliot, J Delaune, A Maignan, S Gillet, L Dequae Merchadou, E Pambrun, A Frosch, J Cohen, V Villes, P Kurkdji, M A Loko, M Winnock

Abstract

Background: Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected patients. Our study aims at identifying the correlates of access to HCV treatment in this population.

Methods: We used 3-year follow-up data from the HEPAVIH ANRS-CO13 nationwide French cohort which enrolled patients living with HIV and HCV. We included pegylated interferon and ribavirin-naive patients (N = 600) at enrolment. Clinical/biological data were retrieved from medical records. Self-administered questionnaires were used for both physicians and their patients to collect data about experience and behaviors, respectively.

Results: Median [IQR] follow-up was 12[12-24] months and 124 patients (20.7%) had started HCV treatment. After multiple adjustment including patients' negative beliefs about HCV treatment, those followed up by a general practitioner working in a hospital setting were more likely to receive HCV treatment (OR[95%CI]: 1.71 [1.06-2.75]). Patients followed by general practitioners also reported significantly higher levels of alcohol use, severe depressive symptoms and poor social conditions than those followed up by other physicians.

Conclusions: Hospital-general practitioner networks can play a crucial role in engaging patients who are the most vulnerable and in reducing existing inequities in access to HCV care. Further operational research is needed to assess to what extent these models can be implemented in other settings and for patients who bear the burden of multiple co-morbidities.

Figures

Figure 1
Figure 1
Distribution of patients according to the specialty of their hospital physician.

References

    1. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–1058. doi: 10.1002/hep.510300409.
    1. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, Jougla E, Semaille C, Morlat P, Salmon D. et al.Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr. 2008;48:590–598. doi: 10.1097/QAI.0b013e31817efb54.
    1. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, Francois M, Burty C. et al.Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19) HIV Med. 2009;10:282–289. doi: 10.1111/j.1468-1293.2008.00686.x.
    1. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, Heripret L, Costagliola D, May T, Chene G. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805. doi: 10.1016/j.jhep.2005.01.022.
    1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S. et al.Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641.
    1. Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care. 2009;25:171–180. doi: 10.1017/S0266462309090229.
    1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D. et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi: 10.1056/NEJMoa020047.
    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. doi: 10.1016/S0140-6736(01)06102-5.
    1. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M. et al.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
    1. Lagging M, Wejstal R, Uhnoo I, Gerden B, Fischler B, Friman S, Josephson F, Karlstrom O, Sangfelt P, Schvarz R, Weiland O. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis. 2009;41:389–402. doi: 10.1080/00365540902998271.
    1. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, Puoti M, Soriano V, Tural C. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9:82–88. doi: 10.1111/j.1468-1293.2007.00535.x.
    1. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754–758. doi: 10.1111/j.1525-1497.2005.0161.x.
    1. Cox J, Graves L, Marks E, Tremblay C, Stephenson R, Lambert-Lanning A, Steben M. Knowledge, attitudes and behaviours associated with the provision of hepatitis C care by Canadian family physicians. J Viral Hepat. 2011;18:e332–e340. doi: 10.1111/j.1365-2893.2010.01426.x.
    1. Gheorghe L, Pascu O, Ceausu E, Csiki IE, Iacob S, Caruntu F, Simionov I, Vadan R. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009. J Gastrointestin Liver Dis. 2010;19:161–167.
    1. Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA. et al.Racial differences in hepatitis C treatment eligibility. Hepatology. 2011;54:70–78. doi: 10.1002/hep.24358.
    1. Sanvisens A, Fuster D, Serra I, Tor J, Tural C, Rey-Joly C, Muga R. Estimated Liver Fibrosis and its Impact on All-Cause Mortality of HCV-Monoinfected and HCV/HIV-Coinfected Drug Users. Curr HIV Res. 2011;9:256–262.
    1. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat. 2010;17:839–844. doi: 10.1111/j.1365-2893.2009.01250.x.
    1. Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, Jeffers L, Ho SB, Johnson D, Schmidt WN. et al.Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772–1779. doi: 10.1111/j.1572-0241.2005.41860.x.
    1. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, Goetz M, Asch SM. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007;46:1741–1749. doi: 10.1002/hep.21927.
    1. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.
    1. Groom H, Dieperink E, Nelson DB, Garrard J, Johnson JR, Ewing SL, Stockley H, Durfee J, Jonk Y, Willenbring ML, Ho SB. Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol. 2008;42:97–106. doi: 10.1097/MCG.0b013e31802dc56f.
    1. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend. 2007;88:49–53. doi: 10.1016/j.drugalcdep.2006.09.018.
    1. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389. doi: 10.1136/gut.2006.099150.
    1. Jauffret-Roustide M, Oudaya L, Rondy M, Le Strat Y, Couturier E, Emmanuelli J, Desenclos JC. Représentations du traitement de l'hépatite C chez les usagers de drogues. Enquête InVS-ANRS Coquelicot, France, 2004-2007. InVS BEH. 2009;20-21:213–216.
    1. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, Parish B, Brown J, Komaromy M, Colleran K. et al.Expanding access to hepatitis C virus treatment- Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52:1124–1133. doi: 10.1002/hep.23802.
    1. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J. et al.Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199–2207. doi: 10.1056/NEJMoa1009370.
    1. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, Casteelen G, van Santen G, van den Berg CH, Coutinho RA. et al.Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011;23:23–31. doi: 10.1097/MEG.0b013e328340c451.
    1. Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A, Phillips AN, Lundgren JD, Euro SSG. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis. 2006;38:1092–1097. doi: 10.1080/00365540600786515.
    1. Cooper CL, Giordano C, Mackie D, Mills EJ. Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Ther Clin Risk Manag. 2010;6:207–212.
    1. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat. 2006;13:678–682. doi: 10.1111/j.1365-2893.2006.00740.x.
    1. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97–100. doi: 10.1086/344907.
    1. Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr. 2004;37:1367–1375. doi: 10.1097/01.qai.0000131932.21612.49.
    1. Nguyen OK, Dore GJ, Kaldor JM, Hellard ME. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int J Drug Policy. 2007;18:447–451. doi: 10.1016/j.drugpo.2007.01.007.
    1. Rey D, Carrieri MP, Spire B, Loubiere S, Dellamonica P, Gallais H, Cassuto GP, Gastaut JA, Obadia Y. Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment. J Urban Health. 2004;81:48–57. doi: 10.1093/jurban/jth087.
    1. Restrepo A, Johnson TC, Widjaja D, Yarmus L, Meyer K, Clain DJ, Bodenheimer HC Jr, Min AD. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat. 2005;12:86–90. doi: 10.1111/j.1365-2893.2005.00548.x.
    1. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, Thomas DL, Sulkowski MS. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361–2369. doi: 10.1097/QAD.0b013e32801086da.
    1. Gidding HF, Law MG, Amin J, Macdonald GA, Sasadeusz JJ, Jones TL, Strasser SI, George J, Dore GJ. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust. 2011;194:398–402.
    1. Perut V, Labalette C, Sogni P, Ferrand I, Salmon-Ceron D, Vidal-Trecan G. Access to care of patients with chronic hepatitis C virus infection in a university hospital: is opioid dependence a limiting condition? Drug Alcohol Depend. 2009;104:78–83. doi: 10.1016/j.drugalcdep.2009.04.002.
    1. Grebely J, Bryant J, Hull P, Hopwood M, Lavis Y, Dore GJ, Treloar C. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat. 2011;18:e104–e116. doi: 10.1111/j.1365-2893.2010.01370.x.
    1. Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA. et al.The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis. 2010;10:303.
    1. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350. doi: 10.1053/j.gastro.2004.11.018.
    1. Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale. Psychiatrie et Psychobiologie. 1989;4:163–166.
    1. Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, Weissman S, Neidig J, Marcus C, Chesney M. et al.Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1):S77–S90.
    1. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56:423–432.
    1. Gache P, Michaud P, Landry U, Accietto C, Arfaoui S, Wenger O, Daeppen JB. The Alcohol Use Disorders Identification Test (AUDIT) as a screening tool for excessive drinking in primary care: reliability and validity of a French version. Alcohol Clin Exp Res. 2005;29:2001–2007. doi: 10.1097/01.alc.0000187034.58955.64.
    1. Heeb JL, Gmel G. Measuring alcohol consumption: a comparison of graduated frequency, quantity frequency, and weekly recall diary methods in a general population survey. Addict Behav. 2005;30:403–413. doi: 10.1016/j.addbeh.2004.04.022.
    1. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–694. doi: 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>;2-R.
    1. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, Keaveney M, Lambert J, McCormick PA, McKiernan S. et al.Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010;24:753–762. doi: 10.1089/apc.2010.0142.
    1. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis. 2005;40(Suppl 5):S313–S320.
    1. Bova C, Ogawa LF, Sullivan-Bolyai S. Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care. 2010;21:63–74. doi: 10.1016/j.jana.2009.07.009.
    1. Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis. 2005;40(Suppl 5):S349–S354.
    1. Baum MK, Jayaweera DT, Duan R, Sales S, Lai S, Rafie C, Regev A, Page JB, Berkman R, Campa A. Quality of life, symptomatology and healthcare utilization in HIV/HCV co-infected drug users in Miami. J Addict Dis. 2008;27:37–48.
    1. Marcellin F, Preau M, Dellamonica P, Ravaux I, Kurkdji P, Protopopescu C, Carrieri MP, Spire B. Adding HCV treatment to HIV treatment in HIV-HCV coinfected patients: the impact on the different dimensions of fatigue and self-reported side effects. J Pain Symptom Manage. 2007;34:413–421. doi: 10.1016/j.jpainsymman.2006.12.014.
    1. Marcellin F, Preau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials. 2007;8:320–327. doi: 10.1310/hct0805-320.
    1. Roux P, Fugon L, Winnock M, Salmon-Ceron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction. 2012;107:152–159. doi: 10.1111/j.1360-0443.2011.03608.x.
    1. Walley AY, White MC, Kushel MB, Song YS, Tulsky JP. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat. 2005;28:181–187. doi: 10.1016/j.jsat.2004.12.004.
    1. Cacoub P, Halfon P, Rosenthal E, Pialoux G, Benhamou Y, Perronne C, Pol S. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol. 2008;48:35–42. doi: 10.1016/j.jhep.2007.07.028.
    1. Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res. 2006;30:1520–1526. doi: 10.1111/j.1530-0277.2006.00183.x.
    1. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction. 2008;103:1828–1836. doi: 10.1111/j.1360-0443.2008.02323.x.
    1. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253–263. doi: 10.1016/S0376-8716(98)00028-3. discussion 267-258.
    1. Grignon M, Perronnin M, Lavis JN. Does free complementary health insurance help the poor to access health care? Evidence from France. Health Econ. 2008;17:203–219. doi: 10.1002/hec.1250.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi